Dr. Sam Hupert, CEO of Pro Medicus, Joins 4Dx Advisory Board
4Dx is pleased to announce the appointment of Dr. Sam Hupert, co-Founder and CEO of Pro Medicus (ASX: PME) to the 4Dx advisory board.
Dr. Hupert has made a private investment into 4Dx and agreed to sit on 4Dx’s advisory board, bringing with him more than 37 years of success as a leader in the global healthcare medtech and imaging IT community. Pro Medicus develops Radiology Information Systems (RIS) and Picture and Archiving and Communication Systems (PACS) for radiology departments across the globe and has been one of the best performing med tech companies on the ASX in recent years (ASX: PME).
“Like Pro Medicus, 4Dx will commercialize its XV Technology through the U.S. market” says 4Dx Founder & CEO Andreas Fouras. “Dr. Hupert’s understanding of this market will be invaluable” says Fouras.
Dr. Hupert will commence his advisory role effective immediately.
4Dx is an innovative software company delivering a new gold standard in respiratory function analysis. The revolutionary four-dimensional technology accurately scans lung function and pulmonary ventilation as the patient breathes, working in combination with traditional x-Ray or CT imaging. The 4Dx technology provides greater sensitivity, resolution and accuracy for respiratory disease quantification and management over the current stand-alone imaging modalities. Our Software-as-a-Service scans enable more comprehensive results by identifying the subtlest variations in lung function while using lower levels of radiation than traditional methods.
Respiratory disease diagnosis and monitoring is a $30 billion p.a. global industry that 4Dx is aiming to disrupt and grow through imaging analysis technology that provides clinicians with greater insight into diseases of the lung. 4Dx will bring about a step change in lung health by providing better information to doctors and patients.
Better information = better decisions = improved patient outcomes